Rationale for dapagliflozin administration for the prevention of adverse outcomes in patients with heart failure with reduced ejection fraction. Expert consensus statement

Những quyển sách tương tự

• Rationale for dapagliflozin administration for the prevention of adverse outcomes in patients with heart failure with reduced ejection fraction. Expert consensus statement
  Bằng: S. N. Tereshchenko, et al.
  Được phát hành: (2020-06-01)
• DAPA-HF trial: dapagliflozin evolves from a glucose-lowering agent to a therapy for heart failure
  Bằng: Edgardo Kaplinsky
  Được phát hành: (2020-02-01)
• Sub-analyses of the DAPA-CKD study: new data on the use of sodium-glucose cotransporter type 2 inhibitor in the treatment of chronic kidney disease
  Bằng: Minara S. Shamkhalova, et al.
  Được phát hành: (2022-11-01)
• The Role of Dapagliflozin in the Management of Heart Failure: An Update on the Emerging Evidence
  Bằng: Gupta M, et al.
  Được phát hành: (2021-08-01)
• SGLT-2 inhibitors: new effective drugs for treatment of heart failure
  Bằng: Olgierd Król, et al.
  Được phát hành: (2022-12-01)